Five-Year Overall Survival Analysis Using First- and Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase in a Prospective Observational Study (SIMPLICITY)

被引：0

作者：

Mauro, Michael ^{[1
]}

Paquette, Ronald ^{[2
]}

Hehlmann, Rudiger ^{[3
]}

Williams, Loretta A. ^{[4
]}

Goldberg, Stuart L. ^{[5
]}

Michallet, Mauricette ^{[6
]}

Gambacorti-Passerini, Carlo ^{[7
]}

Tang, Derek ^{[8
]}

DeGutis, Irene S. ^{[8
]}

McBride, Ali ^{[8
]}

Parsons, Lori ^{[9
]}

Montelongo, Monica Z. ^{[9
]}

Cortes, Jorge E. ^{[10
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[2] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA

[3] Heidelberg Univ, Heidelberg, Germany

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[5] Hackensack Univ, John Theurer Canc Ctr, Med Ctr, Hackensack, NJ USA

[6] Ctr Lutte Canc Leon Berard, Lyon, France

[7] Univ Milano Bicocca, Milan, Italy

[8] Bristol Myers Squibb, Princeton, NJ USA

[9] ICON plc, Blue Bell, PA USA

[10] Augusta Univ, Georgia Canc Ctr, Augusta, GA USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-163080

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

632

引用

页码：9624 / 9625

页数：2

共 50 条

[1] Quality of Life and Symptom Burden With First- and Second-generation Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myeloid Leukemia
Bostan, Hayri
Toptas, Tayfur
Tanrikulu, Funda Pepedil
Kut, Kevser
Arikan, Fatma
Yilmaz, Fergun
Atagunduz, Isik
Firatli-Tuglular, Tulin
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (12): : 836 - 842
[2] Cytogenetic and Molecular Response with First- and Second-Generation Tyrosine Kinase Inhibitor (TKI) Therapy in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)
Cortes, Jorge E.
Chen, Clara
Davis, Catherine
Goldberg, Stuart L.
Mauro, Michael J.
BLOOD, 2019, 134
[3] Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia
Swords R.
Alvarado Y.
Cortes J.
Giles F.J.
Current Hematologic Malignancy Reports, 2007, 2 (2) : 83 - 88
[4] Second generation tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia
le Coutre, P.
Baskaynak, G.
Schwarz, M.
Petereit, C.
Westermann, J.
Dorken, B.
ANNALS OF ONCOLOGY, 2007, 18 : 17 - 17
[5] Improved Drug Adherence in Patients with Chronic Myeloid Leukemia in the Chronic Phase by Switching to Second-Generation Tyrosine Kinase Inhibitors
Maeda, Yasuhiro
Okamoto, Atsushi
Kawaguchi, Shin-ichiro
Konishi, Akiko
Yamamoto, Kenta
Eguchi, Go
Kanai, Yoshitaka
Yamaguchi, Terufumi
ACTA HAEMATOLOGICA, 2017, 138 (03) : 140 - 142
[6] First-generation vs second-generation tyrosine kinase inhibitors: which is best at diagnosis of chronic phase chronic myeloid leukemia?
Oehler, Vivian G.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2020, (01) : 228 - 236
[7] Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia Treated with First- Versus Second-Generation Tyrosine Kinase Inhibitors
Shacham Abulafia, Adi
Shemesh, Sivan
Rosenmann, Lena
Berger, Tamar
Leader, Avi
Sharf, Giora
Raanani, Pia
Rozovski, Uri
JOURNAL OF CLINICAL MEDICINE, 2020, 9 (11) : 1 - 9
[8] Chronic Myeloid Leukemia Therapy: Focus on Second-Generation Tyrosine Kinase Inhibitors
McFarland, K. Leigh
Wetzstein, Gene A.
CANCER CONTROL, 2009, 16 (02) : 132 - 140
[9] Second-Generation Tyrosine Kinase Inhibitors as First-Line Treatment Strategy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients
Breccia, M.
Alimena, G.
CURRENT CANCER DRUG TARGETS, 2012, 12 (04) : 391 - 401
[10] Impact of Second-Generation Tyrosine Kinase Inhibitors As Second Line Treatment for Patients with Chronic Myeloid Leukemia
Valentin Garcia-Gutierrez, J.
Herrera, Pilar
Abalo, Lorena L.
Dolores Rey, Maria
Calbacho, Maria
Ramos, Lourdes
Ramos, Paloma
Montalban, Carlos
Lopez-Jimenez, Javier
BLOOD, 2011, 118 (21) : 1615 - 1615

← 1 2 3 4 5 →